Akeso Secures NMPA Review for Gumokimab in Ankylosing Spondylitis
Event summary
- Akeso (9926.HK) received acceptance for review of its supplemental New Drug Application (sNDA) for gumokimab (AK111) for active ankylosing spondylitis (AS) by the NMPA’s CDE.
- China’s AS patient population is estimated at approximately 4 million.
- This is the second NDA acceptance for gumokimab, following a prior acceptance for psoriasis treatment in January 2025.
- The acceptance is based on positive Phase III clinical trial results (AK111-303) demonstrating efficacy and symptom alleviation.
The big picture
Akeso’s success in China’s biopharmaceutical market is increasingly important as the company seeks to diversify beyond its Hong Kong listing. The acceptance of gumokimab’s NDA underscores the growing demand for novel therapies in China, but also highlights the challenges of navigating the country’s regulatory environment and reimbursement processes. Akeso's focus on innovative therapies, including bispecific antibodies, positions it to capitalize on this demand, but execution risks remain significant.
What we're watching
- Regulatory Timeline
- The speed of NMPA review will be a key indicator of Akeso’s prospects in the Chinese market, particularly given the competitive landscape for biologics.
- Commercialization
- The success of gumokimab will depend on Akeso’s ability to secure reimbursement and distribution within China’s complex healthcare system.
- Pipeline Momentum
- Akeso’s continued advancement of its broader pipeline, including bispecific antibodies like AK139 and AK152, will be crucial for long-term growth and diversification.
Related topics